GRHL3-AS1

Across TCGA pan-cancer cohorts, GRHL3-AS1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of GRHL3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where GRHL3-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GRHL3-AS1 is over-expressed in tumor, although a few such as KIRC and PAAD show the opposite, repressed pattern.

LUAD, LUSC, and THCA are the cancer types where GRHL3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GRHL3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.304	<.001	8	view →
LUSC	Female	All	+0.677	<.001	7	view →
THCA	All	All	+0.097	<.001	7	view →
BLCA	All	III,IV	+0.685	.003	6	view →
COAD	Female	II,III,IV	+0.223	<.001	6	view →
HNSC	All	II,III,IV	+0.208	.006	4	view →
KIRC	All	II,III,IV	−0.113	.002	3	view →
PAAD	Female	All	−0.260	.001	2	view →
BRCA	All	IV	−0.219	.043	2	view →
PRAD	All	All	−0.135	<.001	2	view →
LIHC	All	All	+0.125	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

GRHL3-AS1–LUAD

Open the LUAD breakdown →